Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.
By D. Breems, W. van Putten, G. D. de Greef, S. V. van Zelderen-Bhola, K. Gerssen-Schoorl, C. Mellink, A. Nieuwint, M. Jotterand, A. Hagemeijer, H. Beverloo and 1 more. Journal of Clinical Oncology, 2008
607 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/1238b217e863a8de06f03381550ca7ddeb8db5e7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
Citations in the corpus
- TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. (2012, methodology): “Recently, a new cytogenetic category was introduced, that is, the monosomal karyotype (MK) defined by the presence of one single autosomal monosomy in association with at least one additional autosomal monosomy or one structural chromosomal abnormality (in the absence of core-binding-factor AML and ”
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (2017, background): “Therapy-relatedmyeloid neoplasms (t-MNs) are a distinct category within the WHO classification including cases of t-MDS and t-AML. t-AML is a well recognized clinical syndrome occurring as a late complication following cytotoxic therapy for a primary neoplasm or a nonneoplastic disorder.241,242 Curr”